



E-ISSN: 2278-4136

P-ISSN: 2349-8234

JPP 2019; 8(3): 2089-2093

Received: 08-03-2019

Accepted: 10-04-2019

**Gopiesh Khanna Venkatesan**  
Department of Biotechnology,  
Vels Institute of Science,  
Technology and Advanced  
Studies (VISTAS), Vels  
University, Pallavaram,  
Chennai, Tamil Nadu, India

**Saravanan Devarajan**  
Department of Biotechnology,  
Vels Institute of Science,  
Technology and Advanced  
Studies (VISTAS), Vels  
University, Pallavaram,  
Chennai, Tamil Nadu, India

## A review on complementary and alternative treatments for dementia

**Gopiesh Khanna Venkatesan and Saravanan Devarajan**

### Abstract

Dementia is a kind of brain diseases which causes a progressive decrease in the capability to remember and think. The physical and mental ailments are considered as the main source of dementia disorder. Generally, after Alzheimer's disease (AD), vascular dementia is considered as a second important cause for dementia in 10%-15% of the dementia populace. This malady is described by blood-brain boundary interruption, mitochondrial impairment, oxidative stress, neuroinflammation, and hypometabolism; symptomatic treatments, such as N-methyl- D-aspartate (NMDA) receptor rivals and acetylcholinesterase inhibitors. Methodologies for AD counteractive action by the way of non-pharmacological medicines are related along the way of life intercessions, for example, socialization e mental difficulties, and exercise just like a healthy diet and caloric confinement. AD is essential health problem on which all individuals ought to be informed, so evading strategy that diminish the peril of its advancement might be executed this analysis is intended to give an updated review on the present status of dementia. Different problems in connection to preclinical experimentation and clinical investigation have been distinguished and upcoming exploration bearings are examined.

**Keywords:** Dementia, alzheimer's disease, mitochondrial impairment, neuroinflammation, n-methyl- d-aspartate, hypometabolism

### Introduction

Dementia is a disorder related to continuous hindrances in learning and memory capacity, intellectual aptitudes, exercises of everyday living, daily activities and life's quality. As per the 2015 analysis dementia affected peoples are around 46 million peoples in the world. Every year 7.7 million new persons are affected by dementia disease <sup>[1]</sup>. More than 353,800 peoples have affected by dementia in Australia country. In 2050 it will be raised to 900,000 constantly <sup>[2]</sup>. Second-leading death in Australia is considered as the lung malignant growth and cerebrovascular disease. The most general kind of dementia is Alzheimer's disease. We can see it on around 50-70%. Othe kind of dementias is Lewy body dementia and vascular dementia. Vascular Dementia (VaD) is connected with cardiovascular and cerebrovascular ailments. In western countries, it includes 10-15% of cases <sup>[3]</sup>. In some cases, more than one kind of dementia might exist in the same person. Cardiovascular risk factors play an important role in dementia because poorer control of risk factors may lead to dementia Most of the Vascular Dementia (VaD) noticed in the developing countries which are around 30% <sup>[4]</sup>. Generally, Vascular Dementia (VaD) occurs with AD and other kinds of dementia. When investigation clinically studied 40% Vascular Dementia (VaD) instance also have an AD kind of neurodegenerative pathology <sup>[5]</sup>. It is identified as a well-known category of varied dementia. Presently, glutamate receptor antagonists and cholinesterase inhibitors are considered as a better alternative medicine for AD treatments. Those treatments have likewise been utilized in certain nations for the characteristics alleviation in the person with VaD, yet the wellbeing and the semi impermanent curative advantages of this interference in VaD continue resolutely. Many individuals with VaD or dementia and their careers direct to interrelating treatment, because of the absence of pharmacological adequate therapies. Herbal medicine nutraceuticals, acupuncture, tai chi, yoga, and music therapy are the ordinary flattering medication involvement for VaD and dementia and gamble -concession. Comparative 2000 years previously <sup>[6]</sup> in classical, China was reported in the literature that herbal cure was intact to increase the memory function and grow longevity <sup>[7]</sup> and also consume the herbal drugs for the medication of aging-associated illness. Early clinical and preclinical that confirmed either single herbal preparation or as complex herbal formulation helped to use as an herbal medicine for VaD. This analysis is intended to give a brief review of how to help a portion of the normally utilized plants and herbal association with an accentuation on Chinese herbal drugs for the cure.

### Correspondence

**Gopiesh Khanna Venkatesan**  
Department of Biotechnology,  
Vels Institute of Science,  
Technology and Advanced  
Studies (VISTAS), Vels  
University, Pallavaram,  
Chennai, Tamil Nadu, India

Distribution and difficulties related to herbal medicine are deliberate, and contextual analysis is given to show the advancement procedure of a new complex herbal expression for VaD that exploits current pharmacological and pharmaceuticals progress.

## 2. Pathophysiology and Therapeutic alteration for Vascular Dementia

Intellectual disability (particularly controlling paralysis) is the essential side effect of VaD, which can also produce a disruption in mood and behavior and the decrease of personal satisfaction. As indicated by the veins included and the neurotic method, VaD can be separated into big vessel dementia (multi-infarct dementia or multiple infarcts), small vessel dementia (microinfarction and small vessel disease), hypoperfusion dementia, strategic infarct dementia, dementia associated to angiopathies (amyloid, hypertension), haemorrhagic dementia, and familial vascular dementia. The major determinant related to VaD contains hyperlipidemia, hypertension, genetic disposition, diabetes, cardiac diseases, obesity and physical immobility<sup>[8]</sup>. The pathophysiology of VaD is unpredictable. It assimilates communicate among vascular aetiologies (vascular variables and cerebrovascular scatters), changes in the mind (white matter lesions, infarcts, and atrophy) and host factors (education, age)<sup>[9]</sup>. The ultimate familial aetio pathogenic pathway more often peculiarity to hypoperfusion, hypoxia, or occlusive method ensuring about ischemic destruction in different regions of the brain with resulting intellectual and memory function impedances<sup>[10]</sup>. Different pathogenic factors such as AD, aging, atherosclerosis, and amyloid removal also give to VaD improvement by means of redness, swelling and oxidative stress<sup>[11]</sup>. At present, effectual pharmaceutical intercessions for VaD are inadequate. Standard treatment to a great extent focuses on symptomatic administration and anticipation of additional cerebrum injure by means of realization and control of cardiovascular and cerebrovascular risk utilizing, such as anti-hypertensives, anti-diabetes, statins, aspirin, vascular care and way of life adjustment<sup>[12]</sup>. Various classes of anti-AD pharmaceutical agents are intact off-label for symptomatic manipulation in VaD. Cholinesterase (ChE) inhibitors (galantamine, donepezil, and rivastigmine) and NMDA receptor rivals (memantine) have appeared unassuming temporary clinical advantages in improving cognitive purpose; though these investigations neglect to exhibit considerable upgrades in worldwide execution, the behavior of day by day living, and personal satisfaction<sup>[13]</sup>. The dominant part of studies directed so far is over a generally brief span (5-6 months); in this manner, the long-term advantage and reliability of these intercessions in VaD have not been approved.

## 3. Pharmacological treatment

Alzheimer's disease needs exact determination, too soon if conceivable, and satisfactory etiological cure, and as an operable age-associated neurodegenerative disorder, its specific pathophysiology should be studied. The therapeutic option has concentrated on enhancing the side effects just as decreasing the rate of succession of destruction, despite the fact that this has not fundamentally upturned the infection, so prevention is a superior solution for this general medical issue<sup>[14, 15]</sup>. The lethal compliances of A $\beta$  or tau in the cerebrum are an intention to smear the ailment, and obstruction the production of these peptides might be a component of valuable medications. All things considered, the present

treatment of this illness are supported on cholinesterase inhibitors and a glutamate antagonist, providing just symptomatic relief, while proof for the difficulty and multicausality of this dementia is given that in fundamental and analytic investigations<sup>[16]</sup>. Endeavors in etiology-based medication are as of now in progress in analytic preliminaries, just as supplement production medicines, for example, proper diet, physical activity, cognitive and the management of comorbidity<sup>[17]</sup>.

### 3.1 Neurotransmitter Systems

For AD treatment nicotinic and Muscarinic Ach receptors are also used as a target, even though in clinical trials agonist's selectivity is one of the major problems. Presently EVP-6124 is in phase 2 trial. Depended on the NMDA glutamate cholinergic presents in AD, it is natural to recognize the various Bio Med research International 7 neurotransmitter networks, specifically of the hippocampus. Serotonin receptors are revealed in the part of the CNS associate in memory and learning. The prevention of 5-HT<sub>6</sub> serotonin receptors was present to improve acetylcholine dissipate and few compounds are in different level of analytical experiments, examined an achievable cure for mild to moderate AD. In the brain cognition, relevant structures and memory have Histamine receptors specifically, H<sub>3</sub> receptors contain in an enormous amount. It appears that H<sub>3</sub> receptor antagonists might develop cholinergic neuro transmission. Phase 2 and 1 analysis along antagonists are presently conducted.

### 3.2 Etiology-Based Treatment

As per the above explanation, for sporadic AD ApoE $\epsilon$ 4 is one of the most important genetic risk element, even though, dependent on the amyloid cascade hypothesis for disease-amending medication, amyloid binders and secretase intonation are directing by efforts, additionally directing kinases associated in the hyperphosphorylation of tau protein<sup>[18]</sup>.

### 3.3 Tau Therapies

One of the main focus of the therapy is hyperphosphorylated tau's prevention of aggregates of combined, helically twisted fiber in neurofibrillary. Immunotherapy has a lot of developments. In clinical trials, ACI-35 and AADvac1 are the initially discovered vaccines. Phosphorylation of tau proteins inhibitors like an irreversible GSK-3 $\beta$  inhibitor tideglusib has been analyzed along without expected advantages<sup>[19]</sup> hyper phosphorylation of tau proteins contains cyclin-dependent kinase 5 (CDK5) Above formation is recognized as a possible drug target. In clinical trials, tau aggregations many molecules present to act as an excellent inhibitor. Amongst these drugs, MB (methylene blue) and methylene blue's metabolites azure B and azure A are capable to enhance the protein degradation and inhibit the activities of the caspase-3 and caspase-1. Likewise, leucomethylthioninium with a relevant counter ion LMTX in Phase-3 clinical trials and MTC or methylthioninium chloride (phase-2 clinical trial) have been present to decrease tau aggregation and transgenic mouse models reverse behavioral deficits. Then disease advancement with AD. Still, the actual mechanism of MTC and LMTX produce a neuroprotective response *in vivo* are not entirely realized. Tau aggregations additional hopeful inhibitors are anthraquinones, phenothiazines, benzothiazoles, N-phenylamines, rhodanines.

### 3.4 Other Therapies

As an age-based pathology, AD is associated with further deep-seated-degenerative disorders, and also organized treatments are essential. A type 3 diabetes hypothesis of AD has been advanced, and proper treatment for the disease is intranasal insulin injection. Because of its capability to infiltrate the brain-blood barrier [20]. LDL (Elevated low-density lipoprotein) concentration raises the risk of increasing AD but the statins using secured cure is disputed [21]. Obesity and Dyslipidemia are resulting causative influences in affinity to different diseases such as metabolic syndrome, which consist of, central obesity, insulin resistance hyperglycemia, atherogenic dyslipidemia, hypertension, and a pro-inflammatory and prothrombotic state [22, 23].

### 4. Non pharmacological treatments

Non-pharmacological based treatments are significant for the obviation of AD or as adjuvants in other treatments. AD precaution procedures can be split into two major groups, such as 1) correlate with lifestyle and 2) chemical compounds and diet [24, 25].

#### 4.1 Lifestyle

Lifestyle approaches consist of socialization, mental challenges, physical activity, and energy restriction as preventive influences in AD [26]. Primarily aerobic exercise is widely used to reduce the AD deficits [27]. Aerobic exercise comes under physical activity. This will possible for the minimum number of cases [28].

### 4.2 Diet and Chemical Substances

Dietary supplement for AD prevention was analyzed with vitamins like C, folates, B6, D, B12 and E vitamins. Analysis of vitamin B represents combined results [29]. One report represents the analysis was conducted to 271 patients with the treatments of vitamin B and homocysteine for two years. It shows an important difference when compared to placebo in entire brain atrophy [30]. Further reports represent various results. It has been suggested that folic acid has neuroprotective action through an epigenetic process that prevents amyloid- $\beta$  peptide augmentation [31]. Three years of treatments with AD using the 2000 IU of vitamin E did not show caring results [32]. Nor with the integrate treatment with vitamin C [33,34]. Also, vitamin D increase enhances cognitive functioning [35].

### 4.3 Pro-inflammatory cytokines combined with gut microbiota alteration during aging

Probiotics administration in the elderly may enhance gut health and boost anti-inflammatory functioning [36] since the "microbiota-gut-brain axis" can reduce the neuroinflammatory method. In addition, the advantageous personality of probiotics in AD has been combined along with their creation of metabolites by fermentation, containing SCFAs (short-chain fatty acids) such as butyric acids and propionic acids [37]. A current work represents a neuroprotective activity of *Clostridium butyricum* which revive brain levels of butyrate in a mouse model of vascular dementia [38]. Probiotics raise intestinal barrier integrity by activation epithelial cells protects against pathogens [39].




Fig 1: Non-pharmacological treatments

### 5. Medicinal herbs used for Alzheimer's diseases

The consumer of interrelating medicines, such as herbal extracts, in dementia therapy, modify depending on the various cultural traditions. In orthodox Western medicine, different with that in China and the Far East, for example, the pharmacological ability of traditional cognitive- or memory-enhancing herbs have not been rarely inspected in the relations of present models of Alzheimer's disease [40]. A special case is *Ginkgo Biloba* in which the ginkgolides have antioxidant, neuroprotective and cholinergic functions admissible to Alzheimer's disease mechanisms. The therapeutic potency of Ginkgo extracts in Alzheimer's disease in placebo restrained clinical trials is reputedly like to

presently ordained drugs such as tacrine or donepezil and, significantly, inviting consequence of Ginkgo are minimal [41]. Very Old European reference books, such as those on medicinal plants, document a variety of other herbs such as *Salvia officinalis* (sage) and *Melissa officinalis* (balm) with memory-improving abilities, and cholinergic properties have newly known in extracts of these plants. The Standard for the current invention of clinically related pharmacological properties in herbs with long-secure medicinal use contains, for example, the interaction of alkaloid opioids in *Papaver somniferum* (opium poppy) with endogenous opiate receptors in the brain. With new important in understanding the neurobiology of Alzheimer's disease, and as yet narrow

efficacy of so-called rationally designed therapies, [42] it may be time to re-explore historical archives for the new way in pharmaceutical development.

## 6. Conclusion

As per the survey conducted in 2015 among 44 million peoples in global which represents the major reason for dementia combined with the neurodegenerative disorder is Alzheimer's diseases [43]. AD is a significant health difficulty in which all people should be conversant so that prevention techniques that reduce the exposure of its growth may be applied. AD is a multifactorial disease and for prevention, first pharmacological treatment is the way. Additionally, two or more non-pharmacological treatments are also needed. Which is strengthen the precaution. AD should be easily avoided when the earlier stage of prediction. However, the addition of dietary changes and lifestyle are significant to improve the treatments of dementia patients [44]. For prevention and therapy, Alzheimer's diseases research is necessary to develop for the purpose of new molecules. Numerous methodological problems determined in current clinical trials. In addition to the common issues combined with statistical analysis of the results, randomization process, sample size calculation, many dementia or VAD trial particular problems as well as occur. For instance, diagnostic criteria to determine the VAD or mixed dementia, AD is not defined in many trials. In another kind of trials, various diagnostic criteria like DSM-3-R, ADDTC, NINDS-AIREN, DSM-3, ICD-10, HIS and DSM-4 were used [45]. There is also an absence of consistency in cognitive function assessment process conducting instruments. Also some of the instruments not valid in VaD cohorts/dementia.

## 7. References

- Dementia Fact Sheet, World Health Organisation, 2016.
- Australian Institute of Health and Welfare, Dementia in Australia. Cat. No. AGE 70. Canberra, Canada: AIHW, 2012.
- Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuro pathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. *Lancet Neurology*. 2011; 10(9):785-96.
- Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. *Vascular Health Risk Management*. 2008; 4(2):363-81.
- Kalaria RN. Neuro pathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease. *Acta Neuro pathologic*. 2016; 131(5):659-85.
- Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. *Dementia and Geriatric Cognitive Disorders*. 2008; 25(5):408-422.
- Liu J, Chang D. Vascular dementia. *Journal of Complementary Medicine*. 2006; 5:14-20.
- Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. *Neuro therapeutics*. 2011; 8(3):361-373.
- Liu Chang D. Vascular dementia. *Journal of Complementary Medicine*. 2006; 5:14-20.
- Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. *Neuro therapeutics*. 2011; 8(3):361-373.
- Skoog I. Status of risk factors for vascular dementia. *Neuro epidemiology*. 1998; 17(1):2-9.
- Aggarwal NT, DeCarli C. Vascular dementia: emerging trends. *Seminars in Neurology*. 2007; 27(1):66-77.
- Sachdev P, Brodaty H. Vascular dementia: an Australian perspective. *Alzheimer Disease and Associated Disorders*. 1999; 13(3):S206-S212.
- Shim H. Vascular cognitive impairment and post-stroke cognitive deficits. *Current Neurology and Neuroscience Reports*. 2014; 14(1):418.
- Chu LW. Alzheimer's disease: early diagnosis and treatment. *Hong Kong Medical Journal*. 2012; 18(3):228-237.
- Kumar A, Nisha CM, Silakari C, Sharma I, Anusha K, Gupta N *et al*. Current and novel therapeutic molecules and targets in Alzheimer's disease. *Journal of the Formosan Medical Association*. 2016; 115(1):3-10.
- Scheltens P, Blennow K, Breteler MM, De Strooper B, Frisoni GB, Salloway S, *et al*. Alzheimer's disease. *The Lancet*. 2016; 388(10043):505-17.
- Nelson L, Tabet N. Slowing the progression of Alzheimer's disease; what works? *Ageing Research Reviews*. 2015; 23:193-209.
- Kumar CM, Nisha C, Silakari *et al*. Current and novel therapeutic molecules and targets in Alzheimer's disease. *Journal of the Formosan Medical Association*. 2016; 115(1):3-10.
- Danzysz W, Parsons CG. Alzheimer's disease,  $\beta$ -amyloid, glutamate, NMDA receptors, and memantine-searching for the connections. *Br J Pharmacol*. 2012; 167(2):324-52.
- Sorin Hostiuc, Paula Perlea, Mihai Marinescu, Catalin Dogaroiu, Eduard Drima. GSK-3 Inhibitors, and Tooth Repair: An Ethical Analysis. *Frontiers in Pharmacology*. 2018; 9:1495.
- Godyin J, Jończyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. *Pharmacological Reports*. 2016; 68(1):127-138.
- Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. *Human Molecular Genetics*. 2014; 23(14):3716-3732.
- Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E. Tau protein and tau aggregation inhibitors. *Neuropharmacology*. 2010; 59(5):276-289.
- Dias HKI, Brown CLR, Polidori MC, Lip GYH, Griffiths HR. LDL-lipids from patients with hypercholesterolemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention. *Clinical Science*. 2016; 129(12):1195-1206.
- Lin FC, Chuang YS, Hsieh HM, Lee TC, Chiu KF, Liu CK *et al*. Early statin use and the progression of Alzheimer disease: a total population-based case-control study. *Medicine*. 2015; 94(47):e2143.
- Grundy SM. Metabolic syndrome update. *Trends in Cardiovascular Medicine*. 2016; 26(4):364-373.
- Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: panel for early detection, management, and risk stratification in the West Virginian population. *International Journal of Medical Sciences*. 2016; 13(1):25-38.
- Jedrzejewski MK, Ewbank DC, Wang H, Trojanowski JQ. The impact of exercise, cognitive activities, and socialization on cognitive function: results from the

- national long-term care survey. *American Journal of Alzheimer's Disease & Other Dementias*. 2014; 29(4):372-378.
30. Okonkwo OC, Schultz SA, Oh JM, Larson J, Edwards D, Cook D *et al*. Physical activity attenuates age-related biomarker alterations in preclinical AD. *Neurology*. 2014; 83(19):1753-1760.
  31. Verghese J, Lipton RB, Katz MJ, Hall CB, Derby CA, Kuslansky G *et al*. Leisure activities and the risk of dementia in the elderly. *The New England Journal of Medicine*. 2003; 348(25):2508-2516.
  32. De Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith D. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. *International Journal of Geriatric Psychiatry*. 2012; 27(6):592-600.
  33. Kim H, Kim G, Jang W, Kim SY, Chang N. Association between intake of B vitamins and cognitive function in elderly Koreans with cognitive impairment. *Nutrition Journal*. 2014; 13(1):1-11.
  34. Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese Patients. *Clinical Therapeutics*. 2007; 29(10):2204-2214.
  35. Ford AH, Flicker L, Alfonso H, Thomas J, Clarnette R, Martins R *et al*. Vitamins B12, B6, and folic acid for cognition in older men. *Neurology*. 2010; 75(17):1540-1547.
  36. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S *et al*. Vitamin E and donepezil for the treatment of mild cognitive impairment. *The New England Journal of Medicine*. 2005; 352(23):2379-2388.
  37. Arlt S, Thomsen TM, Beisiegel U, Kontush A. Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease. *Neurochemical Research*. 2012; 37(12):2706-2714.
  38. Gangwar AK, Rawat A, Tiwari S, Tiwari SC, Narayan J, Tiwari S. Role of Vitamin-D in the prevention and treatment of Alzheimer's disease. *Indian Journal of Physiology and Pharmacology*. 2015; 59(1):94-99.
  39. Duncan SH, Flint HJ. Probiotics and prebiotics and health in aging populations. *Maturitas*. 2013; 75(1):44-50.
  40. Lin CS, Chang CJ, Lu CC, Martel J, Ojcius DM, Ko YF *et al*. Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. *Biomedical Journal*. 2014; 37(5):259-268.
  41. Liu J, Sun J, Wang F, Yu X, Ling Z, Li H *et al*. Neuro protective effects of *Clostridium butyricum* against vascular dementia in mice via metabolic butyrate. *Bio Med Research International*. 2015; 2015:1-12.
  42. Prescott D, Lee J, Philpott DJ. An epithelial armamentarium to sense the microbiota. *Seminars in Immunology*. 2013; 25(5):323-333.
  43. Rizzi L, Rosset I, Cruz MR. Global Epidemiology of Dementia: Alzheimer's and Vascular Types. *BioMed Research International*. 2014; 2014:1-4.
  44. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. Medicinal Plants and Alzheimer's Disease: From Ethnobotany To Phytotherapy. *Journal of Pharmacy and Pharmacology*. 1999; 51(5):527-34.
  45. Hostiuc S, Perlea P, Marinescu M, Dogaroiu C, Drima E. GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis. *Front Pharmacol*. 2019; 9:1495.